425 related articles for article (PubMed ID: 22940548)
1. Optimization of formulation and process parameters for the production of nanosuspension by wet media milling technique: effect of Vitamin E TPGS and nanocrystal particle size on oral absorption.
Ghosh I; Schenck D; Bose S; Ruegger C
Eur J Pharm Sci; 2012 Nov; 47(4):718-28. PubMed ID: 22940548
[TBL] [Abstract][Full Text] [Related]
2. Nanosuspension for improving the bioavailability of a poorly soluble drug and screening of stabilizing agents to inhibit crystal growth.
Ghosh I; Bose S; Vippagunta R; Harmon F
Int J Pharm; 2011 May; 409(1-2):260-8. PubMed ID: 21371540
[TBL] [Abstract][Full Text] [Related]
3. A quality-by-design study to develop Nifedipine nanosuspension: examining the relative impact of formulation variables, wet media milling process parameters and excipient variability on drug product quality attributes.
Patel PJ; Gajera BY; Dave RH
Drug Dev Ind Pharm; 2018 Dec; 44(12):1942-1952. PubMed ID: 30027778
[TBL] [Abstract][Full Text] [Related]
4. Application of spray granulation for conversion of a nanosuspension into a dry powder form.
Bose S; Schenck D; Ghosh I; Hollywood A; Maulit E; Ruegger C
Eur J Pharm Sci; 2012 Aug; 47(1):35-43. PubMed ID: 22565066
[TBL] [Abstract][Full Text] [Related]
5. Formulation, optimization and in vitro-in vivo evaluation of febuxostat nanosuspension.
Ahuja BK; Jena SK; Paidi SK; Bagri S; Suresh S
Int J Pharm; 2015 Jan; 478(2):540-52. PubMed ID: 25490182
[TBL] [Abstract][Full Text] [Related]
6. Fabrication of surfactant-stabilized nanosuspension of naringenin to surpass its poor physiochemical properties and low oral bioavailability.
Singh MK; Pooja D; Ravuri HG; Gunukula A; Kulhari H; Sistla R
Phytomedicine; 2018 Feb; 40():48-54. PubMed ID: 29496174
[TBL] [Abstract][Full Text] [Related]
7. Application of the combinative particle size reduction technology H 42 to produce fast dissolving glibenclamide tablets.
Salazar J; Müller RH; Möschwitzer JP
Eur J Pharm Sci; 2013 Jul; 49(4):565-77. PubMed ID: 23587645
[TBL] [Abstract][Full Text] [Related]
8. Development of an amorphous nanosuspension by sonoprecipitation-formulation and process optimization using design of experiment methodology.
Gajera BY; Shah DA; Dave RH
Int J Pharm; 2019 Mar; 559():348-359. PubMed ID: 30721724
[TBL] [Abstract][Full Text] [Related]
9. Curcumin-loaded solid lipid nanoparticles with Brij78 and TPGS improved in vivo oral bioavailability and in situ intestinal absorption of curcumin.
Ji H; Tang J; Li M; Ren J; Zheng N; Wu L
Drug Deliv; 2016; 23(2):459-70. PubMed ID: 24892628
[TBL] [Abstract][Full Text] [Related]
10. Study of effect of variables on particle size of telmisartan nanosuspensions using box-Behnken design.
Rao MR; Bajaj A
Drug Res (Stuttg); 2014 Dec; 64(12):663-7. PubMed ID: 24549965
[TBL] [Abstract][Full Text] [Related]
11. Preparation and in vitro/in vivo evaluation of fenofibrate nanocrystals.
Zuo B; Sun Y; Li H; Liu X; Zhai Y; Sun J; He Z
Int J Pharm; 2013 Oct; 455(1-2):267-75. PubMed ID: 23876497
[TBL] [Abstract][Full Text] [Related]
12. Effect of four different size reduction methods on the particle size, solubility enhancement and physical stability of nicergoline nanocrystals.
Martena V; Shegokar R; Di Martino P; Müller RH
Drug Dev Ind Pharm; 2014 Sep; 40(9):1199-205. PubMed ID: 23815299
[TBL] [Abstract][Full Text] [Related]
13. Identifying the correlation between drug/stabilizer properties and critical quality attributes (CQAs) of nanosuspension formulation prepared by wet media milling technology.
George M; Ghosh I
Eur J Pharm Sci; 2013 Jan; 48(1-2):142-52. PubMed ID: 23085547
[TBL] [Abstract][Full Text] [Related]
14. Development of curcumin nanocrystal: physical aspects.
Rachmawati H; Al Shaal L; Müller RH; Keck CM
J Pharm Sci; 2013 Jan; 102(1):204-14. PubMed ID: 23047816
[TBL] [Abstract][Full Text] [Related]
15. Enhancement of Curcumin Solubility by Phase Change from Crystalline to Amorphous in Cur-TPGS Nanosuspension.
Shin GH; Li J; Cho JH; Kim JT; Park HJ
J Food Sci; 2016 Feb; 81(2):N494-501. PubMed ID: 26766628
[TBL] [Abstract][Full Text] [Related]
16. Identification of critical process parameters and its interplay with nanosuspension formulation prepared by top down media milling technology--a QbD perspective.
Ghosh I; Schenck D; Bose S; Liu F; Motto M
Pharm Dev Technol; 2013; 18(3):719-29. PubMed ID: 23061898
[TBL] [Abstract][Full Text] [Related]
17. An Extrusion Spheronization Approach to Enable a High Drug Load Formulation of a Poorly Soluble Drug with a Low Melting Surfactant.
Tatavarti A; Kesisoglou F
J Pharm Sci; 2015 Nov; 104(11):3752-3759. PubMed ID: 26205160
[TBL] [Abstract][Full Text] [Related]
18. Spray drying of a poorly water-soluble drug nanosuspension for tablet preparation: formulation and process optimization with bioavailability evaluation.
Sun W; Ni R; Zhang X; Li LC; Mao S
Drug Dev Ind Pharm; 2015 Jun; 41(6):927-33. PubMed ID: 24785575
[TBL] [Abstract][Full Text] [Related]
19. Novel powder formulations for controlled delivery of poorly soluble anticancer drug: application and investigation of TPGS and PEG in spray-dried particulate system.
Mu L; Teo MM; Ning HZ; Tan CS; Feng SS
J Control Release; 2005 Apr; 103(3):565-75. PubMed ID: 15820404
[TBL] [Abstract][Full Text] [Related]
20. Process parameter dependent growth phenomena of naproxen nanosuspension manufactured by wet media milling.
Bitterlich A; Laabs C; Krautstrunk I; Dengler M; Juhnke M; Grandeury A; Bunjes H; Kwade A
Eur J Pharm Biopharm; 2015 May; 92():171-9. PubMed ID: 25766272
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
